Stock News Iovance Biotherapeutics falls 6% on Q2 2022 bottom line miss admin Admin posted on 2 years ago 259 views Iovance Therapeutics (IOVA) is down 6% in after-hours trading after its Q2 2022 financial results missed on the bottom line. Iovance Biotherapeutics falls 6% on Q2 2022 bottom line missAug. 04, 2022 7:19 PM ETIovance Biotherapeutics, Inc. (IOVA)By: Jonathan Block, SA News Editor Zerbor admin Follow Comments Comment 0 comment Best Oldest Newest Write the first comment for this!
Comments
0 comment